WB | 咨询技术 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 1/10000 | Human,Mouse,Rat |
Aliases | S3 |
WB Predicted band size | 27 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse, Rat |
Immunogen | Full length fusion protein |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL-22抗体的3篇代表性文献,按规范格式整理:
1. **文献名称**:*The biology of interleukin-22: A novel mediator of mucosal immunity and tissue repair*
**作者**:James P. Di Santo, et al.
**摘要**:综述IL-22在黏膜免疫和上皮组织修复中的作用,探讨其通过抗体靶向治疗肠道炎症、银屑病等疾病的潜力。
2. **文献名称**:*Interleukin-22 neutralization ameliorates murine colitis by modulating IL-22-STAT3 signaling*
**作者**:Chenyu Zhang, et al.
**摘要**:研究IL-22中和抗体在实验性结肠炎模型中的疗效,证明其通过抑制STAT3通路减轻肠道炎症和上皮损伤。
3. **文献名称**:*Therapeutic targeting of IL-22 and IL-22 antibodies in inflammatory skin diseases*
**作者**:Curtis D. Hodge, et al.
**摘要**:比较IL-22及其抗体在银屑病和特应性皮炎中的作用,揭示抗体通过阻断IL-22R1信号通路改善皮肤屏障功能。
如需扩展,可补充IL-22抗体在癌症或感染中的研究(如*Nature* 2021年关于IL-22抗体抑制肝癌进展的论文)。
Interleukin-22 (IL-22), a member of the IL-10 cytokine family, is primarily produced by immune cells such as Th17 cells, γδ T cells, and innate lymphoid cells. It plays a dual role in health and disease by binding to the IL-22 receptor (IL-22R1/IL-10R2 complex) expressed on epithelial and stromal cells. IL-22 promotes tissue repair, mucosal barrier integrity, and antimicrobial defense but can also drive inflammation and pathological processes in autoimmune disorders, chronic infections, and cancer. Dysregulated IL-22 signaling is implicated in psoriasis, inflammatory bowel disease (IBD), and liver fibrosis, making it a therapeutic target.
IL-22 antibodies, including neutralizing monoclonal antibodies (mAbs), are designed to block IL-22-IL-22R interactions, inhibiting downstream STAT3 signaling. Preclinical studies demonstrate their efficacy in reducing inflammation and tissue damage in models of psoriasis and colitis. However, challenges remain in balancing therapeutic benefits with potential risks, as IL-22 blockade may impair epithelial regeneration and host defense. Conversely, agonist antibodies mimicking IL-22’s protective effects are explored for enhancing tissue repair in acute injuries or infections.
Current research focuses on optimizing antibody specificity, delivery, and safety profiles. Clinical trials for IL-22-targeting biologics are ongoing, highlighting their potential as precision therapies for immune-mediated diseases while underscoring the need to contextualize IL-22's pleiotropic functions in different pathologies.
×